TFF Pharmaceuticals, Inc. – NASDAQ:TFFP
TFF Pharmaceuticals stock price today
$0.135
+0.07
+107.69%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 4 hours
TFF Pharmaceuticals stock price monthly change
-96.75%
month
TFF Pharmaceuticals stock price quarterly change
-96.75%
quarter
TFF Pharmaceuticals stock price yearly change
-80.36%
year
TFF Pharmaceuticals key metrics
Market Cap | 288.79K |
Enterprise value | N/A |
P/E | -0.68 |
EV/Sales | N/A |
EV/EBITDA | 0.98 |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -10.20 |
Revenue | N/A |
EBITDA | -20.39M |
Income | -19.92M |
Revenue Q/Q | 295.24% |
Revenue Y/Y | 1722.20% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeTFF Pharmaceuticals stock price history
TFF Pharmaceuticals stock forecast
TFF Pharmaceuticals financial statements
| Jun 2023 | 0 | -5.02M | |
|---|---|---|---|
| Sep 2023 | 0 | -4.40M | |
| Dec 2023 | 733.87K | -4.76M | -648.94% |
| Mar 2024 | 203.27K | -5.73M | -2821.4% |
| Mar 2024 | 203.27K | -5.73M | -2821.4% |
|---|---|---|---|
| Sep 2025 | 0 | -1.51M | |
| Oct 2025 | 203.27K | -668.61K | -328.92% |
| Dec 2025 | 203.27K | -692.49K | -340.67% |
Analysts Price target
Financials & Ratios estimates
0%
Yield TTM
| Payout ratio | 0% |
|---|
| 2019 | 2.37% |
|---|---|
| 2020 | |
| 2021 | |
| 2022 | |
| 2023 |
| Jun 2023 | 13569309 | 1.28M | 9.49% |
|---|---|---|---|
| Sep 2023 | 14885171 | 1.19M | 8.02% |
| Dec 2023 | 12027316 | 2.46M | 20.46% |
| Mar 2024 | 9186550 | 3.88M | 42.26% |
| Jun 2023 | -4.45M | -35.70K | -59.22K |
|---|---|---|---|
| Sep 2023 | -3.00M | -12.65K | 5.08M |
| Dec 2023 | -4.21M | -46.39K | 567 |
| Mar 2024 | -3.14M | 0 | 901.13K |
TFF Pharmaceuticals alternative data
| Aug 2023 | 15 |
|---|---|
| Sep 2023 | 15 |
| Oct 2023 | 15 |
| Nov 2023 | 15 |
| Dec 2023 | 15 |
| Jan 2024 | 15 |
| Feb 2024 | 15 |
| Mar 2024 | 15 |
| Apr 2024 | 15 |
| May 2024 | 19 |
| Jun 2024 | 19 |
| Jul 2024 | 19 |
TFF Pharmaceuticals other data
13.58%
-14.86%
of TFFP is owned by hedge funds
20
-20
4.07M
-3.14M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Sep 2022 | 0 | 40255 |
| Nov 2022 | 65205 | 0 |
| Dec 2022 | 50000 | 0 |
| Mar 2023 | 190000 | 0 |
| Aug 2023 | 820000 | 216000 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | CARLSON CAPITAL L P 10 percent owner | Common Stock | 1,000 | $0.39 | $392 | ||
Purchase | WEISMAN HARLAN F director, officer: President an.. | Common Stock | 600,000 | $0.25 | $150,000 | ||
Purchase | ROCAMBOLI STEPHEN director | Common Stock | 20,000 | $0.25 | $5,000 | ||
Purchase | ROBERTS BRANDI director | Common Stock | 20,000 | $0.25 | $5,000 | ||
Purchase | MILLS ROBERT S director | Common Stock | 40,000 | $0.25 | $10,000 | ||
Purchase | MIKHAK ZAMANEH officer: Chief Medical Officer | Common Stock | 120,000 | $0.25 | $30,000 | ||
Purchase | COLEMAN KIRK ALLEN officer: Chief Fi.. | Common Stock | 20,000 | $0.25 | $5,000 | ||
Sale | CARLSON CAPITAL L P 10 percent owner | Common Stock, par value $0.001 per share (the "Common Stock" | 215,000 | $0.44 | $93,955 | ||
Purchase | MIKHAK ZAMANEH officer: Chief Medical Officer | Common Stock | 15,000 | $0.82 | $12,300 | ||
Purchase | WEISMAN HARLAN F director, officer: President an.. | Common Stock | 150,000 | $0.88 | $131,850 |
| Quarter | Transcript |
|---|---|
| Q3 2023 14 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 15 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Q3 2022 14 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Q2 2022 12 Aug 2022 | Q2 2022 Earnings Call Transcript |
TFF Pharma: The Potential Is Still Very Much Present
TFF Pharmaceuticals: Q3 Data Is Pivotal In So Many Ways
TFF Pharmaceuticals: A Highly Attractive Basket Of Options
TFF Pharmaceuticals: Upside Catalysts Starting To Show Up Amid Omicron, But Timidly
TFF Pharma's Platform Is Highly Relevant In The Battle Against The Pandemic
Selecta Biosciences Has Multiple Shots On Goal
TFF Pharmaceuticals: Looking Attractive At These Prices
-
What's the price of TFF Pharmaceuticals stock today?
One share of TFF Pharmaceuticals stock can currently be purchased for approximately $0.14.
-
When is TFF Pharmaceuticals's next earnings date?
Unfortunately, TFF Pharmaceuticals's (TFFP) next earnings date is currently unknown.
-
Does TFF Pharmaceuticals pay dividends?
No, TFF Pharmaceuticals does not pay dividends.
-
How much money does TFF Pharmaceuticals make?
TFF Pharmaceuticals has a market capitalization of 288.79K.
-
What is TFF Pharmaceuticals's stock symbol?
TFF Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "TFFP".
-
What is TFF Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of TFF Pharmaceuticals?
Shares of TFF Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are TFF Pharmaceuticals's key executives?
TFF Pharmaceuticals's management team includes the following people:
- Mr. Glenn R. Mattes Pres, Chief Executive Officer & Director(age: 70, pay: $654,170)
- Mr. Kirk Allen Coleman Chief Financial Officer, Treasurer & Sec.(age: 52, pay: $361,670)
- Mr. Christopher Cano Chief Operating Officer & Vice President of Bus. Devel.(age: 54, pay: $343,120)
-
How many employees does TFF Pharmaceuticals have?
As Jul 2024, TFF Pharmaceuticals employs 19 workers, which is 27% more then previous quarter.
-
When TFF Pharmaceuticals went public?
TFF Pharmaceuticals, Inc. is publicly traded company for more then 5 years since IPO on 25 Oct 2019.
-
What is TFF Pharmaceuticals's official website?
The official website for TFF Pharmaceuticals is tffpharma.com.
-
Where are TFF Pharmaceuticals's headquarters?
TFF Pharmaceuticals is headquartered at 1751 River Run, Austin, TX.
-
How can i contact TFF Pharmaceuticals?
TFF Pharmaceuticals's mailing address is 1751 River Run, Austin, TX and company can be reached via phone at +81 74386168.
TFF Pharmaceuticals company profile:
TFF Pharmaceuticals, Inc.
tffpharma.comExchange:
NASDAQ
Full time employees:
19
Industry:
Biotechnology
Sector:
Healthcare
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as cannabidiol substance for the treatment of various epilepsy syndromes, as well as anxiety, insomnia, and various pain; Inhaled SARS-CoV2 Monoclonal Antibody for the treatment of patients with COVID-19 infections; Niclosamide Inhalation Powder to treat tapeworm infections in humans, as well as COVID-19 disease; and other vaccines. The company has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop inhaled SARS-CoV2 monoclonal antibody; and a licensing and collaboration agreement with UNION therapeutics A/S. The company was incorporated in 2018 and is based in Austin, Texas.
1751 River Run
Austin, TX 76107
Austin, TX 76107
CIK: 0001733413
ISIN: US87241J2033
CUSIP: 87241J104
